Long-term effects of cladribine tablets treatment on cognition, relapses, MRI, and safety outcomes in patients with relapsing multiple sclerosis: 4-year results from the CLARIFY-MS Extension study

被引：0
|
作者：
Selmaj, Krzysztof [1 ,2 ]
Langdon, Dawn [3 ]
Brochet, Bruno [4 ]
Solari, Alessandra [5 ]
Havrdova, Eva Kubala [6 ,7 ]
Patti, Francesco [8 ,9 ]
Piehl, Fredrik [10 ]
Smyk, Andrzej [11 ]
Lehn, Annette [11 ]
Nolting, Axel [11 ]
Montalban, Xavier [12 ]
Lechner-Scott, Jeannette [13 ,14 ]
机构：
[1] Ctr Neurol, Lodz, Poland
[2] Univ Warmia & Mazury, Dept Neurol, Olsztyn, Poland
[3] Royal Holloway Univ London, Dept Psychol, Egham, Surrey, England
[4] Univ Bordeaux, INSERM U 1215, Bordeaux, France
[5] Fdn IRCCS Ist Neurol Carlo Besta, Unit Neuroepidemiol, Milan, Italy
[6] Charles Univ Prague, Med Fac 1, Dept Neurol, Prague, Czech Republic
[7] Ctr Clin Neurosci, Prague, Czech Republic
[8] Univ Catania, Dept Med & Surg Sci & Adv Technol, GF Ingrassia, Catania, Italy
[9] Univ Catania, Azienda Osped Univ Policlin G Rodolico San Marco, Catania, Italy
[10] Karolinska Inst, Dept Clin Neurosci, Stockholm, Sweden
[11] Merck Healthcare KGaA, Darmstadt, Germany
[12] Univ Hosp Vall dHebron, Dept Neurol Neuroimmunol, Ctr Multiple Sclerosis Catalonia Cemcat, Barcelona, Spain
[13] Univ Newcastle, Newcastle, NSW, Australia
[14] John Hunter Hosp, Div Neurol, Newcastle, NSW, Australia
来源：
MULTIPLE SCLEROSIS JOURNAL | 2024年 / 30卷 / 03期
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
P846/1650
引用
收藏
页码：655 / 657
页数：3
相关论文
共 50 条
  • [1] Long-term effects of cladribine tablets on MRI activity outcomes in patients with relapsing-remitting multiple sclerosis: the CLARITY Extension study
    Comi, Giancarlo
    Cook, Stuart
    Rammohan, Kottil
    Sorensen, Per Soelberg
    Vermersch, Patrick
    Adeniji, Abidemi K.
    Dangond, Fernando
    Giovannoni, Gavin
    THERAPEUTIC ADVANCES IN NEUROLOGICAL DISORDERS, 2018, 11 : 1 - 11
  • [2] Treatment satisfaction in patients with highly-active relapsing multiple sclerosis treated with cladribine tablets: clarify-ms study interim analysis
    Brochet, B.
    Hupperts, R. H. Raymond
    Langdon, D.
    Solari, A.
    Piehl, F.
    Lechner-Scott, J.
    Montalban, X.
    Selmaj, K.
    Valis, M.
    Rejdak, K.
    Havrdova, E. Kubala
    Patti, F.
    Alexandri, N.
    Nolting, A.
    Keller, B.
    MULTIPLE SCLEROSIS JOURNAL, 2020, 26 (3_SUPPL) : 623 - 623
  • [3] Treatment Satisfaction in Patients with Highly-active Relapsing Multiple Sclerosis Treated with Cladribine Tablets: CLARIFY-MS Study Interim Analysis
    Brochet, Bruno
    Hupperts, Raymond
    Langdon, Dawn
    Solari, Alessandra
    Piehl, Fredrik
    Lechner-Scott, Jeanette
    Montalban, Xavier
    Selmaj, Krzysztof
    Valis, Martin
    Havrdova, Eva
    Rejdak, Konrad
    Patti, Francesco
    Alexandri, Nektaria
    Nolting, Axel
    Keller, Birgit
    NEUROLOGY, 2021, 96 (15)
  • [4] Long-term effectiveness of cladribine tablets over 4 years in relapsing multiple sclerosis: Results from the MAGNIFY-MS Extension study
    De Stefano, Nicola
    Vermersch, Patrick
    Wiendl, Heinz
    Barkhof, Frederik
    Montalban, Xavier
    Achiron, Anat
    Derfuss, Tobias
    Chan, Andrew
    Prat, Alexandre
    Leocani, Letizia
    Schmierer, Klaus
    Sellebjerg, Finn
    Lehn, Annette
    Smyk, Andrzej
    Nolting, Axel
    Koelbach, Ralf
    Hodgkinson, Suzanne
    MULTIPLE SCLEROSIS JOURNAL, 2024, 30 (03) : 374 - 376
  • [5] Treatment satisfaction, safety, and tolerability of cladribine tablets in patients with highly active relapsing multiple sclerosis: CLARIFY-MS study 6-month interim analysis
    Brochet, Bruno
    Hupperts, Raymond
    Langdon, Dawn
    Solari, Alessandra
    Piehl, Fredrik
    Lechner-Scott, Jeannette
    Montalban, Xavier
    Selmaj, Krzysztof
    Valis, Martin
    Rejdak, Konrad
    Havrdova, Eva K.
    Patti, Francesco
    Alexandri, Nektaria
    Nolting, Axel
    Keller, Birgit
    MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2022, 57
  • [6] Stabilization of Cognitive Function in Patients With Highly Active Relapsing Multiple Sclerosis Treated With Cladribine Tablets During the 2-Year CLARIFY-MS study
    Langdon, D.
    Brochet, B.
    Havrdova, E. K.
    Lechner-Scott, J.
    Montalban, X.
    Patti, F.
    Piehl, F.
    Selmaj, K.
    Solari, A.
    Alexandri, N.
    Nolting, A.
    Lehn, A.
    Smyk, A.
    MULTIPLE SCLEROSIS JOURNAL, 2023, 29 : 60 - 61
  • [7] MRI outcomes from the long-term extension study of tolebrutinib in patients with relapsing multiple sclerosis: 2-year results
    Reich, D. S.
    Traboulsee, A.
    Syed, S.
    Xu, Z.
    Turner, T. J.
    Arnold, D. L.
    MULTIPLE SCLEROSIS JOURNAL, 2022, 28 (3_SUPPL) : 334 - 335
  • [8] MRI Outcomes from the Long-term Extension Study of Tolebrutinib in Patients with Relapsing Multiple Sclerosis: 2-Year Results
    Reich, Daniel
    Traboulsee, Anthony
    Syed, Sana
    Xu, Zhixing
    Turner, Timothy
    Arnold, Douglas
    NEUROLOGY, 2023, 100 (17)
  • [9] MRI outcomes from the long-term extension study of tolebrutinib in relapsing MS: Year 1 results
    Reich, D. S.
    Traboulsee, A.
    Syed, S.
    Dukovic, D.
    Turner, T.
    Arnold, D. L.
    MULTIPLE SCLEROSIS JOURNAL, 2021, 27 (2_SUPPL) : 571 - 571
  • [10] Safety and efficacy outcomes from the long-term extension study of tolebrutinib in patients with relapsing MS: Year 1 results
    Oh, J.
    Syed, S.
    Orogun, L.
    Matta, A.
    Dukovic, D.
    Fox, R.
    MULTIPLE SCLEROSIS JOURNAL, 2021, 27 (2_SUPPL) : 571 - 572
12345